Intra Cellular Therapies reported $107.66M in Operating Expenses for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Acadia Pharmaceuticals ACAD:US $ 228.48M 53.07M
Aptinyx Inc APTX:US $ 19.38M 207K
Biocryst Pharmaceuticals BCRX:US $ 99.88M 56.38M
Biogen BIIB:US $ 1921.1M 225.6M
Bristol Myers Squibb BMY:US $ 9.1B 247M
Cytokinetics CYTK:US $ 81.7M 4.39M
Esperion Therapeutics ESPR:US $ 61.82M 9.2M
Gilead Sciences GILD:US $ 6393M 89M
Halozyme Therapeutics HALO:US $ 41.61M 3.86M
Intra Cellular Therapies ITCI:US $ 107.66M 4.02M
JAZZ PHA JAZZ:US $ 726.17M 121.18M
Johnson & Johnson JNJ:US $ 17.56B 2.4B
Marinus Pharmaceuticals MRNS:US $ 30.9M 2.26M
Minerva Neurosciences NERV:US $ 7.99M 13.39M
Nektar Therapeutics NKTR:US $ 141.38M 3.46M
Neurocrine Biosciences NBIX:US $ 307.5M 40.8M
Novartis NVS:US 9.96B 998M
Prothena PRTA:US 39.1M 4.83M
Supernus Pharmaceuticals SUPN:US $ 150.54M 2.41M
United Therapeutics UTHR:US $ 175.6M 69.8M
Vanda Pharmaceuticals VNDA:US $ 67.86M 8.48M